Success Metrics

Clinical Success Rate
79.4%

Based on 27 completed trials

Completion Rate
79%(27/34)
Active Trials
3(7%)
Results Posted
52%(14 trials)
Terminated
7(17%)

Phase Distribution

Ph phase_2
15
37%
Ph early_phase_1
2
5%
Ph not_applicable
4
10%
Ph phase_4
3
7%
Ph phase_1
16
39%

Phase Distribution

18

Early Stage

15

Mid Stage

3

Late Stage

Phase Distribution40 total trials
Early Phase 1First-in-human
2(5.0%)
Phase 1Safety & dosage
16(40.0%)
Phase 2Efficacy & side effects
15(37.5%)
Phase 4Post-market surveillance
3(7.5%)
N/ANon-phased studies
4(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

27 of 36 finished

Non-Completion Rate

25.0%

9 ended early

Currently Active

3

trials recruiting

Total Trials

41

all time

Status Distribution
Active(4)
Completed(27)
Terminated(9)
Other(1)

Detailed Status

Completed27
Terminated7
Recruiting3
Withdrawn2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
3
Success Rate
79.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (5.0%)
Phase 116 (40.0%)
Phase 215 (37.5%)
Phase 43 (7.5%)
N/A4 (10.0%)

Trials by Status

withdrawn25%
completed2766%
recruiting37%
terminated717%
not_yet_recruiting12%
unknown12%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT05210374Phase 1

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Recruiting
NCT07477457Phase 2

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting
NCT03323346Phase 2

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

Recruiting
NCT01777919Phase 2

Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform

Not Yet Recruiting
NCT02715609Phase 1

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed
NCT03891667Phase 1

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Completed
NCT02671890Phase 1

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Terminated
NCT03363659Phase 2

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Terminated
NCT04265274Phase 2

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn
NCT03950830Phase 2

Disulfiram and Cisplatin in Refractory TGCTs.

Completed
NCT04485130Phase 2

DISulfiram for COvid-19 (DISCO) Trial

Terminated
NCT00729300Phase 1

A Study of the Relationship Between Disulfiram and Cocaine Self-administration.

Completed
NCT04521335Phase 1

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Terminated
NCT04502589Phase 1

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Completed
NCT04594343Phase 2

Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19

Completed
NCT02770378Phase 1

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed
NCT02963051Phase 1

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Terminated
NCT02678975Phase 2

Disulfiram in Recurrent Glioblastoma

Completed
NCT02735577Phase 4

Neural Mechanisms of Disulfiram Effects

Completed
NCT00913484Phase 2

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Completed

Drug Details

Intervention Type
DRUG
Total Trials
41